An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Acronyms FERWON-EXT
- Sponsors Pharmacosmos
- 10 Mar 2020 Results published in the ClinicalTrials.gov Trial Registry
- 12 Dec 2018 Status changed from active, no longer recruiting to completed.
- 14 Mar 2018 Planned End Date changed from 1 Oct 2020 to 1 Nov 2018.